WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596250
CAS#: 1146594-87-7
Description: JNJ-40418677 is a γ-secretase modulator that selectively blocks γ-site cleavage of the APP without affecting processing of Notch. In human neuroblastoma cells and rat primary neuronal cultures, JNJ-40418677 blocked secretion of Aβb42 (IC50 = 20 nM), with no affects on total Ab concentration, Notch signaling or COX activity. In vivo experiments showed that JNJ-40418677 dose dependently inhibited Aβ42 accumulation in the brain while promoting an increase in Aβ38.
MedKoo Cat#: 596250
Name: JNJ-40418677
CAS#: 1146594-87-7
Chemical Formula: C26H22F6O2
Exact Mass: 480.1524
Molecular Weight: 480.45
Elemental Analysis: C, 65.00; H, 4.62; F, 23.73; O, 6.66
Synonym: JNJ-40418677; JNJ 40418677; JNJ40418677;
IUPAC/Chemical Name: (S)-2-(4,4''-bis(trifluoromethyl)-[1,1':3',1''-terphenyl]-5'-yl)-4-methylpentanoic acid
InChi Key: RQOWDDLKGBMJFX-QHCPKHFHSA-N
InChi Code: InChI=1S/C26H22F6O2/c1-15(2)11-23(24(33)34)20-13-18(16-3-7-21(8-4-16)25(27,28)29)12-19(14-20)17-5-9-22(10-6-17)26(30,31)32/h3-10,12-15,23H,11H2,1-2H3,(H,33,34)/t23-/m0/s1
SMILES Code: O=C(O)[C@@H](CC(C)C)C1=CC(C2=CC=C(C(F)(F)F)C=C2)=CC(C3=CC=C(C(F)(F)F)C=C3)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 480.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Hamilton JY, Sarlah D, Carreira EM. Iridium-catalyzed enantioselective allyl-alkene coupling. J Am Chem Soc. 2014 Feb 26;136(8):3006-9. doi: 10.1021/ja412962w. Epub 2014 Feb 12. PubMed PMID: 24521052.
2: Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA, Tran CH, Terak EC, Raffa RB. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther. 2014 Feb;39(1):25-37. doi: 10.1111/jcpt.12112. Epub 2013 Dec 8. Review. PubMed PMID: 24313554.
3: Van Broeck B, Chen JM, Tréton G, Desmidt M, Hopf C, Ramsden N, Karran E, Mercken M, Rowley A. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol. 2011 May;163(2):375-89. doi: 10.1111/j.1476-5381.2011.01207.x. PubMed PMID: 21232036; PubMed Central PMCID: PMC3087138.
